126 related articles for article (PubMed ID: 12610329)
1. Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI 571): effect of low dosage in an advanced tumour with exon 11 mutation.
Högenauer C; Langner C; Lipp RW; Höfler G; Krejs GJ; Hinterleitner TA
Eur J Gastroenterol Hepatol; 2003 Mar; 15(3):323-7. PubMed ID: 12610329
[TBL] [Abstract][Full Text] [Related]
2. STI571: a magic bullet?
Verweij J; Judson I; van Oosterom A
Eur J Cancer; 2001 Oct; 37(15):1816-9. PubMed ID: 11576833
[No Abstract] [Full Text] [Related]
3. Advanced gastrointestinal stromal tumors successfully treated with imatinib mesylate: a report of two cases.
Hasan S; Hassan M; Oke L; Dinh K; Onojobi G; Lombardo F; Dawkins F; Jack M
J Natl Med Assoc; 2003 Dec; 95(12):1208-10. PubMed ID: 14717479
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
5. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Demetri GD
Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
[TBL] [Abstract][Full Text] [Related]
6. Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate.
Reichardt P; Schneider U; Stroszczynski C; Pink D; Hohenberger P
J Clin Pathol; 2004 Feb; 57(2):215-7. PubMed ID: 14747457
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function.
Bauer S; Hagen V; Pielken HJ; Bojko P; Seeber S; Schütte J
Anticancer Drugs; 2002 Sep; 13(8):847-9. PubMed ID: 12394270
[TBL] [Abstract][Full Text] [Related]
8. Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour.
Miyagawa S; Fujimoto H; Ko S; Hirota S; Kitamura Y
Br J Dermatol; 2002 Aug; 147(2):406-7. PubMed ID: 12174137
[No Abstract] [Full Text] [Related]
9. Metastatic gastrointestinal stromal tumor with an exon 11 c-kit mutation responding to the tyrosine kinase inhibitor imatinib.
Cho H; Kobayashi O; Tsuburaya A; Sugiyama Y; Sairenji M; Motohashi H; Yoshida T; Miyagi Y; Imada T
Dig Surg; 2004; 21(1):74-7. PubMed ID: 14967957
[No Abstract] [Full Text] [Related]
10. [Effect of imatinib treatment of gastrointestinal stromal tumors].
Eckhardt S; Pápai Z; Bodoky G; Horti J; Tamás K; Nagy T; Orosz Z; Sápi Z; Gödény M; Jakab K; Esik O; Trón L; Besznyák I
Orv Hetil; 2003 Nov; 144(45):2207-12. PubMed ID: 14686005
[TBL] [Abstract][Full Text] [Related]
11. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
Demetri GD; von Mehren M; Blanke CD; Van den Abbeele AD; Eisenberg B; Roberts PJ; Heinrich MC; Tuveson DA; Singer S; Janicek M; Fletcher JA; Silverman SG; Silberman SL; Capdeville R; Kiese B; Peng B; Dimitrijevic S; Druker BJ; Corless C; Fletcher CD; Joensuu H
N Engl J Med; 2002 Aug; 347(7):472-80. PubMed ID: 12181401
[TBL] [Abstract][Full Text] [Related]
13. Downstaging of an advanced gastrointestinal stromal tumor by neoadjuvant imatinib.
de Vos tot Nederveen Cappel RJ; van Hillegersberg R; Rodenhuis S; Peterse JL; van Coevorden F
Dig Surg; 2004; 21(1):77-9. PubMed ID: 14967958
[No Abstract] [Full Text] [Related]
14. Complete remission of recurrent gastrointestinal stromal tumors after treatment with imatinib: report of a case.
Kobayashi M; Okamoto K; Nakatani H; Okabayashi T; Namikawa T; Ichikawa K; Kitagawa H; Araki K
Surg Today; 2006; 36(8):727-32. PubMed ID: 16865518
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors.
Kitamura Y; Hirota S; Nishida T
Cancer Sci; 2003 Apr; 94(4):315-20. PubMed ID: 12824897
[TBL] [Abstract][Full Text] [Related]
16. Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors.
George S; Desai J
Curr Treat Options Oncol; 2002 Dec; 3(6):489-96. PubMed ID: 12392638
[TBL] [Abstract][Full Text] [Related]
17. [Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].
Nishida T; Yoshidome K; Tori M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():452-6. PubMed ID: 23513883
[No Abstract] [Full Text] [Related]
18. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
19. Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas.
Heinrich MC; Corless CL
Cancer Treat Res; 2004; 120():129-50. PubMed ID: 15217222
[No Abstract] [Full Text] [Related]
20. Gastrointestinal stromal tumours.
Connolly EM; Gaffney E; Reynolds JV
Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
